Print  |  Close

A Phase 2, Multicenter, Open-label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects With Relapsed / Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)


Active: Yes
Cancer Type: Ewing Sarcoma NCT ID: NCT03441360
Trial Phases: Phase II Protocol IDs: E7389-G000-223 (primary)
NCI-2018-00749
Eligibility: 12 Months - 18 Years, Male and Female Study Type: Treatment
Study Sponsor: Eisai Inc
NCI Full Details: http://clinicaltrials.gov/show/NCT03441360

Summary

This study will be conducted as an assessment of the safety and preliminary activity of eribulin mesylate in pediatric participants with relapsed / refractory rhabdomyosarcoma (RMS), non-rhabdomyosarcoma soft tissue sarcoma (NRSTS), or Ewing sarcoma (EWS) to determine whether each cohort warrants further investigation.